Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

0.8085 +0.0886 (+12.31%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 346,974
Open 0.7000
Bid (Size) 0.7520 (10)
Ask (Size) 0.8085 (15)
Prev. Close 0.7199
Today's Range 0.7400 - 0.8085
52wk Range 0.7000 - 5.750
Shares Outstanding 76,721,543
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
ADC Therapeutics to Participate in September Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire

Performance

YTD
-77.48%
-77.48%
1 Month
-35.32%
-35.32%
3 Month
-59.58%
-59.58%
6 Month
-59.17%
-59.17%
1 Year
-82.65%
-82.65%

More News

Read More
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
From ADC Therapeutics SA
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
Via Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
Via Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
Via Benzinga
ADC Therapeutics Stock Is Plunging Today - What's Going On?
Via Benzinga
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
From ADC Therapeutics SA
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.